MDT Medtronic (MDT) Q4 FY25 earnings call
Medtronic concluded FY25 with robust Q4 performance, extending its streak of mid-single-digit organic revenue growth, driven by strong contributions from Cardiovascular, Neuroscience, and Diabetes segments. The company announced its intent to separate the Diabetes business via an IPO and spin-off within 18 months, aiming to enhance focus and profitability for both entities. Despite anticipated tariff headwinds and increased investments in FY26, management projects a return to high single-digit EPS growth in FY27, underpinned by continued growth drivers and the benefits of the Diabetes separati
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
MDT operating KPIs by quarter
| KPI | Jan 2026 Q3 FY26 | Apr 2026 Q4 FY26 | Jul 2026 Q1 FY27 | Change vs prior quarter |
|---|---|---|---|---|
| Installed base Touch Surgery | 1,000+This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally.Source: earnings call transcript | 1,400+And our Touch Surgery Digital Ecosystem, well, it continues to represent a clear advantage with over 1,400 installations, up 30% plus sequentially.Source: earnings call transcript | 1,500+Today, Touch Surgery is used in more than 1,500 operating rooms globally, supporting AI-powered insights, collaboration and workflows.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.